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Abstract African trypanosomes contain a cytosolic serine 
oligopeptidase, called OP-Tb, that is reversibly inhibited by the 
active principles of three of the five most commonly used 
trypanocidal drugs: pentamidine, diminazene and suramin. OP- 
Tb was inhibited by pentamidine in a competitive manner, and by 
suramin in a partial, non-competitive manner. The inhibition of 
OP-Tb by a variety of suramin analogues correlated with the 
trypanocidal efficacy of these analogues (P= 0.03; by paired 
Student's t-test). Since intracellular (therapeutic) concentrations 
of pentamidine and suramin are reported to reach approximately 
206Kj and 15Ki respectively, we suggest that these drugs may 
exert part of their trypanocidal activity through the inhibition of 
OP-Tb. 
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serine peptidases by suramin [10-12] raised the possibility that 
suramin might inhibit OP-Tb. Furthermore, OP-Tb activity is 
abolished in the presence of thiol-reactive compounds [9], and 
since melarsoprol forms adducts with thiol-containing pro- 
teins via disulfide bonds [13,14], it was also possible that mel- 
arsoprol could inactivate OP-Tb. Here we report that penta- 
midine, diminazene and suramin are indeed inhibitors of OP- 
Tb, and that, in the case of pentamidine and suramin, the 
inhibition of OP-Tb by these inhibitors is likely to be of in 
vivo significance. This represents the first report where pep- 
tidases have been identified as possible targets of trypanocidal 
drugs and we suggest that serine peptidase inhibitors may 
represent a class of lead compounds for the development of 
new chemotherapeutic agents that are active against OP-Tb. 
Recent reports of drug resistance by African trypanosomes 
[15 17] underscore the importance of developing new and 
improved therapeutic strategies. 
1. Introduction 2. Materials and methods 
African trypanosomes are protozoan parasites that cause 
widespread isease in livestock (e.g. cattle) as well as in hu- 
mans. Collectively, the diseases are referred to as African 
trypanosomiasis. A number of drugs are available for the 
chemotherapy of African trypanosomiasis, including sulfo- 
nated naphthylamines such as suramin [1]; aromatic diami- 
dines, including pentamidine [2] and diminazene [3]; the tri- 
valent arsenical, melarsoprol [4]; and e~-DL-difluoromethyl- 
ornithine (DFMO), a suicide inhibitor of ornithine decarbox- 
ylase [5]. With the exception of DFMO, the in vivo targets of 
the drugs have not been unequivocally identified. Conse- 
quently, the biochemical basis of their trypanocidal action is 
unclear [6]. During the course of our studies on the peptidases 
of African trypanosomes, we have identified and purified a 
cytosolic [7] oligopeptidase from the African trypanosome 
To'panosoma brucei brucei, which we called OP-Tb [8,9]. 
The substrate specificity of OP-Tb, which preferentially 
cleaves peptides after pairs of basic amino acid residues 
[8,9], suggested that the aromatic diamidines (pentamidine 
and diminazene), would act as competitive inhibitors of OP- 
Tb. Similarly, previous reports of the inhibition of trypsin-like 
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2.1. Materials 
Melarsoprol and melarsen oxide were from Dr. Alan Fairlamb, 
Biomedical Sciences Institute, University of Dundee. DFMO was 
from Dr. Andrew Peregrine, International Livestock Research Insti- 
tute, Nairobi, Kenya. Suramin was from Bayer (Leverkusen, Ger- 
many). Berenil was from Hoechst VeterinS, r (Munich, Germany). Pen- 
tamidine and diminazene aceturate (minimum 90% purity) were from 
Sigma (St. Louis, MO, USA). The structure of suramin (Fig. 1) illus- 
trates that it is a symmetrical molecule and that each half, connected 
by a central urea group, can be sub-divided into three regions: an 
acidic naphthalene moiety (R1), a methylbenzoyl moiety (R2) and a 
benzoyl (R:I) moiety. Analogues were synthesized as described previ- 
ously [18] with various ubstitutions at RL, R~ and R:~ (Tables 1 and 
2). Analogue nomenclature is adapted from that described in [19]. 
~~a 0~~ NaO~ O~Na 
... : 'N,Ti . "'" i 
Rl R2 R~ R: R2' Rl' 
Fig. 1. Chemical formula of snramln and designated nomenclature 
for suramin analogues (modified from [18,19]). 
1)014-5793/98/$19.00 'G 1998 Federation of European Biochemical Societies. All rights reserved. 
Pll: $00 I 4 -5793(98)009 14-4 
252 
2.2. &olation of OP-Tb 
OP-Tb was purified from 7~ b. brucei clone ILTat 1.1 [9] and active 
enzyme concentration determined using 4-methylumbelliferyl-p-guani- 
dobenzoate as described [20]. 
2.3. Diagnosis of inhibition mechanism 
Inhibition mechanisms were diagnosed from the effect of a drug on 
the K,~, and V~ ..... OP-Tb (1.5 ng, 18.75 fmol active concentration) was 
pre-incubated in assay buffer (50 mM Tris-HCl, 10 mM dithiothreitol, 
pH 8) for 10 min at 37°C, with or without drug, followed by the 
addition of substrate. The initial steady-state v locity was determined 
by continuous assay for a range of substrate concentrations (45 nM- 
75 gM). While the kinetic data are represented graphically as Line- 
weaver-Burk plots (Fig. 2), due to the inherent error in the determi- 
nation of these parameters graphically [21], actual values for K~,~ and 
V, ..... were determined by hyperbolic regression using the software 
package Hyper 1.01 (obtained from Dr. J.S. Easterby, University of 
Liverpool, UK). The k,.~t was determined from k,.~t = V,,~J[E]0, where 
[E]0 represents the active enzyme concentration. Dithiothreitol was 
omitted from assays involving organo-arsenicals to prevent potential 
complex formation of arsenic with free thiols [22]. Organo-arsenicals 
were made up as stock solutions in dimethylformamide, and diluted 
with assay buffer, while the other inhibitors were made up as aqueous 
stock solutions. In the case of melarsoprol and melarsen oxide, the K,, 
and V,,,~,x values were determined in the presence of residual concen- 
trations of dimethylformamide, in order to negate the effect of this 
solvent on these parameters. Non-competitive inhibition was distin- 
guished from irreversible inhibition by diluting out the inhibitory 
effect of compounds exhibiting either mode of inhibition. This was 
achieved with a succession of four dilution/concentration cycles where 
enzyme-inhibitor samples were diluted with assay buffer and concen- 
trated to the original volume in 3 ml polysulfone concentrators 
(7000 × g, 10°C). Trypsin and chymotrypsin were assayed as described 
previously [12]. 
2.4. Cah'ulation of inhibition constant 
For competitive inhibitors, the apparent Ki (Ki0~pp)) was determined 
in the presence of Cbz-Arg-Arg-AMC as previously described [23], 
and corrected for the presence of substrate (Km=245 nM) by dividing 
the Kil~pp) by the factor I+[S]/Km to give the true Ki [23]. For partial 
non-competitive inhibitors, the K~ was determined from the complex 
steady-state rate equation of Baici [24] as modified by Szedlacsek et al. 
[25], 
vi l,o--v~ {l/Tl+G o~K~ ~_ lx~2+41+(Y  (1Ki 
vo- 2v,, V~-~ [E]0 +[  ]o J c~+cy [El0 + 
~,,,+v. 1+o aK~ [I] 
+ (l) 
~,,,-,,~ c~ +,~ [E]o [E]o 
where 6 = [S]/K,,,, v. = [3 k,.~t [E]o[S]/[S]+ctK~. The parameters ~ and [3 
are dimensionless factors representing the change in the Km and k,,~t, 
respectively, in the presence of an inhibitor and v, is the rate extrapo- 
lated at infinite inhibitor concentration, [I]. Once Kin, k~.~t, a and 
had been determined separately, the Ki was calculated by non-linear 
regression analysis, fitting (vj, [I]) pairs to Eq. 1, in which all other 
parameters were fixed. 
2.5. CytotoxiciO: assays 
Trypanosomes were cultured [26] and cytotoxicity assays performed 
as previously described [27]. Cultures were maintained in 24-well cell- 
culture plates (1 ml culture volume). Drugs were dissolved in dime- 
thylsulfoxide, and added at various concentrations to trypanosome 
cultures. The final dimethylsulfoxide concentration was maintained 
at 1% (v/v). Control cultures (without drugs, but containing 1% (v/ 
v) dimethylsulfoxide) were incubated under the same conditions. Cell 
numbers were determined (in triplicate) with a hemocytometer, and 
data analyzed graphically, plotting growth inhibition versus drug con- 
centration, from which the effective concentration inhibiting the 
growth of trypanosome populations by 50% (EC~0) was calculated. 
3. Results and discussion 
The trivalent arsenicals, melarsoprol or melarsen oxide, and 
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Fig. 2. Diagnosis of inhibition mechanisms by trypanocidal drugs. 
Lineweaver-Burk plots of kinetic data obtained for the inhibition of 
Cbz-Arg-Arg-AMC hydrolysis by OP-Tb over a range of inhibitor 
concentrations for (A) pentamidine, (B) Berenil and (C) suramin. 
the ornithine analogue DFMO had no effect on the hydrolysis 
of Cbz-Arg-Arg-AMC by OP-Tb relative to uninhibited con- 
trols (data not shown). However, OP-Tb activity is enhanced 
in the presence of reducing agents and polyamines [8]. Since 
melarsoprol therapy depletes intracellular reducing agents 
(namely trypanothione) and since DFMO therapy depletes 
intracellular polyamine levels [28] either drug may down-reg- 
ulate OP-Tb activity within trypanosomes through the deple- 
tion of intracellular OP-Tb activators. 
OP-Tb was competitively inhibited by pentamidine with a 
Ki of 3,4 gM (Fig. 2A), which compares well with the K~ 
observed for bovine ~-trypsin (2,3 ~aM) [29], bovine mast- 
cell tryptase (1.2 gM) [30] and human plasmin (3.3 btM) 
[31]. Pentamidine isethionate is the active principle of the 
trypanocidal drug Pentacarinate. The mechanism of its trypa- 
nocidal activity is not understood, although it has previously 
been attributed to inhibition of trypanosome S-adenosyl-L- 
methionine decarboxylase [32] or to the intercalation with 
trypanosome DNA [33]. Structurally, the pentamidine mole- 
cule represents two benzamidine molecules joined together, 
resembling a pair of basic amino acid (arginine) residues in 
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Fig. 3. Effect of suramin on substrate hydrolysis by serine proteases. 
A: Effect of increasing concentrations of suramin on the activity of 
OP-Tb (20 nM) against Cbz-Arg-Arg-AMC (~), chymotrypsin (25 
nM) against Suc-Leu-Tyr-AMC (O) and trypsin (25 riM) against 
Cbz-Arg-AMC (©t. Ordinates (vflv,,), initial rate in the presence of 
suramin/initial rate in the absence of suramin. B: Effect of NaCI on 
the inhibition of OP-Tb (20 nM) activity against Cbz-Arg-Arg- 
AMC by suramin (IlL Error bars represent the mean vi/v,,+_SD. 
(n=3). All substrates at 5 p.M. 
a dipeptide. During therapeutic regimens, pentamidine typi- 
cally reaches concentrations of up to 13 laM in the host blood- 
stream [34] where it has a plasma half-life of 47 h [35]. Fur- 
thermore, pentamidine is actively concentrated by 
trypanosomes which possess pentamidine transporters [36], 
reaching intracellular concentrations of between 700 btM and 
1 mM in 3 h [37]. For an inhibitor to be considered physio- 
logically relevant, its in vivo concentration must be > 10K~ 
[38]. As the intracellular concentration of pentamidine within 
trypanosomes i  likely to reach at least 700 btM (=206K~) 
during therapeutic regimes, it is possible that pentamidine 
may exert its trypanocidal activity through the inhibition of 
OP-Tb, which is a cytosolic enzyme. 
Commercially available preparations of the trypanocidal 
drug Berenil contain 45'7,, (m/m) diminazene aceturate, and 
55% (m/m) phenyldimethyl pyrazolone [39]. Diminazene ace- 
turate is the active principle of this drug and is known to 
inhibit S-adenosyl-L-methionine decarboxylase [32] and extra- 
nuclear DNA synthesis in trypanosomes [40]. However, the 
mechanism of the trypanocidal activity of diminazene has 
not been unequivocally determined. Diminazene is like pen- 
tamidine in that it resembles two benzamidine molecules 
joined together, albeit with a shorter spacer region, Thus, 
like pentamidine, it also mimics potential substrates for OP- 
Tb. This structural similarity to pentamidine suggests that 
diminazene molecules may behave similarly with respect o 
OP-Tb, within the parasites. Berenil exhibited mixed inhibi- 
tion of OP-Tb (Fig. 2B). This raises the possibility that the 
diminazene aceturate competitively inhibits OP-Tb activity, 
while the phenyldimethyl pyrazolone contributes to the inhib- 
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ition of OP-Tb by Berenil in a non-competitive manner. How- 
ever, similar data were obtained using a 90°/,, pure preparation 
of diminanizene aceturate (results not shown), suggesting that 
diminazene aceturate itself is entirely responsible for the 
mixed inhibition observed. 
Suramin is known to inhibit a number of serine peptidases. 
These include kallikrein, thrombin and plasmin [10], C I ester- 
ase [11] and trypsin [41]. However, the mechanism is un- 
known. Kinetic analysis of kallikrein inhibition by suramin 
revealed that it was not competitive. More detailed analysis 
of the suramin interaction with neutrophil elastase, cathepsin 
G and proteinase 3 indicated that suramin was a non-com- 
petitive inhibitor of these enzymes [12]. Here we show that the 
suramin inhibition of OP-Tb activity against Cbz-Arg-Arg- 
AMC resulted in a 4.5-fold reduction in V, ..... with no appar- 
ent effect on K,,, (Fig. 2C). As it was possible to dilute out the 
effect of suramin with a series of tour dilution/concentration 
cycles (results not shown), the inhibition by suramin was re- 
versible, and therefore non-competitive. The clustering of the 
V, ...... values at high suramin concentrations (ordinate, Fig. 
2C) suggested that a partial inhibition mechanism was oper- 
ating [1224,25], and this did indeed prove to be the case (Fig. 
3A). The [E]JKi ratio for the inhibition of OP-Tb by suramin 
was <0.01, indicating that there was no tight binding of 
inhibitor to enzyme [38]. A similar situation was observed 
for the inhibition of neutrophil proteinase 3 by suramin, 
which also exhibited partial, non-competitive inhibition by 
suramin with an [E]JKi ratio <0.01 [12]. 
In general there is a good relationship between the basicity 
of an enzyme and its affinity for suramin [12], but this rule 
appears to break down with OP-Tb which has a pl  of 5.1 [7]. 
However. despite its low pl, OP-Tb has 24 lysine residues and 
59 arginine residues (unpublished ata). We suspect hat the 
sulfonic acid groups of suramin electrostatically interact with 
these basic residues, a conclusion supported by the observa- 
tion that NaC1 abolished the inhibition of OP-Tb by suramin 
(Fig. 3B). However, additional specific interactions appear to 
be involved, as polysulfonated glycosaminoglycans such as 
heparin do not inhibit OP-Tb (unpublished ata), suggesting 
that the inhibition is not due to a non-specific electrostatic 
effect with polysulfonated compounds. 
Both suramin and its demethylated analogue ~N F037, Table 
1) were potent inhibitors of OP-Tb activity, and were equally 
trypanocidal. These findings contrast with those of Forneau et 
al. [42], who reported that demethylation of suramin resulted 
in complete loss of trypanocidal activity. However, the EC~ 
values reported here were determined in vitro, whereas For- 
neau et al. [42] investigated the ability of suramin analogues 
to cure trypanosome infection in vivo, in mice. Taken togeth- 
er, these data suggest hat, while the methyl groups are un- 
important for OP-Tb-inhibitory activity and trypanocidal 
efficacy, they may be essential for the metabolism and/or 
transport of suramin in mice. 
Both the number and spatial arrangement of the sulfonic 
acid groups on the aminonaphthyl (R~) moiety were impor- 
tant for inhibitory and trypanocidal activity. Replacing each 
of the l-naphthylamino-4,6,8-trisulfonic acid moieties of sur- 
amin with aniline-2,4-disulfonic a id (NF065: Table 1) re- 
sulted in a 12-fold increase in Ki, but only a 15% increase 
in EC~0. Removal of a second sulfonate group from each of 
the aniline moieties in NF065 (NF078; Table 1) elevated the 
Ki 25-fold when compared with suramin. This weak inhibitor 
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Table I 
Inhibition constants and ECs0 values for symmetrical suramin analogues 
R.E. Morty et al./FEBS Letters 433 (1998) 251 256 
Analogue Structural substituents 
Rl = Rl' R2 = R2" R3 = R3' 
SO3Na O NF037 Nao~~ ,. o " J~"  
~N"" 
SO3Na -. O 0 Suramin N~O3~ ~~ ~ 
° °°° 
Ctt 3 H 
NF031 I N,,.. ",. 
NF065 N.o~s ... o . .~ . . .  
NaO3~ SO3Na ~ " "  NF013 -. absent 
so~s,,,~~. .. o absent NF058 N,O~ ' ~  ~~. . .  
NaO~S /N~. a 3 H / ~'~ CH 3 H 
so~~~ .. o absent 
NF023 NaO, NaO3SI I~ I~/~" ~~, .  
CH 3 H 
Ki EC50 
(pM) (l.tM) 
5.4 74.5 
6.7 88.2 
62.2 96.7 
77.3 104.3 
127.7 128.7 
159.2 167.4 
161.0 172.2 
167.2 >220.0 
Analogue nomenclature is detailed in [19]. 
possessed no trypanocidal activity at the concentrations 
tested. 
It is apparent from Tables 1 and 2 that the length of the 
molecule is also important for both inhibitory potency and 
trypanocidal ctivity. Removal of the benzoyl (Ra) group of 
suramin (NF058; Table 1) increased the K~ 24-fold and the 
ECs0 two-fold. Demethylation of the methylbenzoyl (R2) moi- 
ety of this shortened molecule (to generate NF023 from 
NF058; Table 1) had little effect on Ki or ECsu when com- 
pared with NF058. This is in agreement with our findings that 
these methyl groups are not important for inhibitory or tryp- 
anocidal activity. 
Replacement of both the methylbenzoyl (R2) and benzoyl 
(R:0 groups of suramin with 4-C-benzoyl groups (NF031; 
Table 1) elevated the Ki nine-fold, with a 10% increase in 
ECs(). Subsequent removal of two of these 4-C-benzoyl groups 
R.L Mor O, et aLIFEBS Letters 433 (1998) 251 256 
Table 2 
Inhibition constants and ECr,{~ values for asymmetrical nd half-suramin analogues 
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Analogue Chemical structure 
NF033 N ,o ,s~o,~,  ~ 
¢'r-N 
NaO3S IT" N '  ~ O 
NF035 ~.o ,~~,~.  
NF036 ~.o,~~~~.~ 
el 
SO~Na 
Ki 
308.8 
n.m.  
n .m.  
n .m.  
ECso 
(].tM) 
>220.0 
>220.0 
>220.0 
>220.0 
n.m. denotes that no inhibitory activity was observed at the concentrations tested. Analogue nomenclature is detailed in [19]. 
(NF013; Table 1) increased the Ki 19-fold and the ECs0 by 
31% when compared with suramin. This indicated that a re- 
duction in the length of the molecule was accompanied by a 
reduction in both inhibitory and trypanocidal activity. 
The importance of the length and symmetry of the molecule 
is also illustrated by the lack of inhibitory or trypanocidal 
activity of the 'half-suramin' analogue NF036 (Table 2). Nei- 
ther the rearrangement of one of the sulfonate groups on the 
naphthylene ring (NF035; Table 2), nor the attachment of the 
4,6,8-substituted aminonaphthylsulfonate to a 5-nitro-2-furyl 
group (NF226; Table 2) improved the inhibitory or trypano- 
cidal activity. 
In the absence of a three-dimensional structure of OP-Tb, it 
is difficult to predict how suramin may interact, in such a 
specific fashion, with OP-Tb. Hart et al. [43] examined the 
interactions of suramin and trypanosome phosphoglycerate 
kinase (PGK). Computer modelling of a putative PGK-sur- 
amin complex illustrated that electrostatic interactions 
between PGK and suramin would bridge the PGK active 
site and block the mechanism of action of the enzyme. How- 
ever, it is premature to speculate whether or not suramin may 
somehow occlude the active-site 'pit' proposed to exist in 
oligopeptidases [44]. 
There was a significant correlation (P= 0.03, by paired Stu- 
dent's t-test; Table 1) between the inhibitory potency and 
trypanocidal efficacy of suramin analogues, which strongly 
suggests that OP-Tb represents an important intracellular tar- 
get for suramin. During treatment regimens, suramin reaches 
concentrations of approximately 100 laM within the host 
bloodstream [45] and, although not actively concentrated in
the parasite, it reaches intracellular concentrations of approx- 
imately 100 laM [6]. Since suramin has a Ki of 6.7 laM for OP- 
Tb, the inhibition of OP-Tb by suramin may be physiologi- 
cally relevant and this may explain, at least in part, the try- 
panocidal action of suramin, which remains unelucidated [6]. 
The trypanocidal action of suramin has previously been 
attributed to the inhibition of trypanosome glycolytic en- 
zymes, and while Ki values for the inhibition of these enzymes 
by suramin have not been determined, ICa~ values of 10-100 
BM have been reported [46]. Additionally, a Ki of 15 laM has 
been reported for the inhibition of trypanosome 6-phospho- 
gluconate dehydrogenase by suramin [47]. However, Wang [6] 
pointed out that all nine glycolytic enzymes are protected 
from cytosolic suramin by compartmentalization n a glyco- 
some, wbich is unlikely to take up suramin by diffusion or 
endocytosis. Suramin has been used for over 70 years [6] and 
appears till to be effective against the parasite as there are 
few reports of T. b. brucei resistance [48]. As trypanosomes do 
not readily develop resistance to suramin, it seems likely that 
the drug may act on multiple targets in the parasite. Given 
that the K~ for the inhibition of OP-Tb by suramin is lower 
than that reported for other enzymes, as well as the significant 
correlation between trypanocidal efficacy and OP-Tb inhibi- 
tion, and the cytosolic location of OP-Tb, we propose that 
OP-Tb is one of these targets. 
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